An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
Open Access
- 26 June 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1406247
Abstract
Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc. With the accumulation of anthracycline drugs in the body, they can induce serious heart damage, limiting their clinical application. The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and delves into the molecular mechanisms behind these injuries. Cardiac damage primarily involves alterations in myocardial cell function and pathological cell death, encompassing mitochondrial dysfunction, topoisomerase inhibition, disruptions in iron ion metabolism, myofibril degradation, and oxidative stress. Mechanisms of uptake and transport in anthracycline-induced cardiotoxicity are emphasized, as well as the role and breakthroughs of iPSC in cardiotoxicity studies. Selected novel cardioprotective therapies and mechanisms are updated. Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.Keywords
This publication has 204 references indexed in Scilit:
- Exercise intervention decreases acute and late doxorubicin‐induced cardiotoxicityCancer Medicine, 2021
- The Novel Butyrate Derivative Phenylalanine-Butyramide Protects from Doxorubicin-Induced CardiotoxicityEuropean Journal of Heart Failure, 2019
- Quantitative proteomic profiling identifies new renal targets of copper(II)‐selective chelation in the reversal of diabetic nephropathy in ratsProteomics, 2009
- Cardioprotective interventions for cancer patients receiving anthracyclines2008
- Pathology of radiation and anthracycline cardiotoxicityPediatric Blood & Cancer, 2005
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in ratsJournal of Applied Toxicology, 2001
- Clinical trials with adriamycinCancer, 1971
- Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesiusBiotechnology and Bioengineering, 1969
- Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemiaCancer, 1967